Brought to you by 
Galapagos NV
http://www.glpg.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galapagos NV
August User Fee Calendar Features Gene Therapy, Analgesics, And Of Course Oncology
Sixteen applications are in line for US FDA decisions in August. Ten are novel agents.
AbbVie Says Botox Business Recovering But Allergan Drags Down Q2 Financials
AbbVie reported revenue growth during the second quarter, with products like Rinvoq and Skyrizi leading the charge. But Allergan, despite growth for Vraylar and Ubrelvy, pushed down overall performance.
Remdesivir Should Give Gilead’s 2020 Revenue A Needed Lift
As it prepares to report second quarter earnings that may show coronavirus-related impacts, the company’s antiviral for COVID-19 may boost 2020 revenue and offset need for new products.
EMA Says Yes To GSK’s Belantamab But Rejects Tagraxofusp & Emapalumab
GlaxoSmithKline's first-of-its kind treatment for multiple myeloma is among 11 new medicines that have won an EU approval nod from the European Medicines Agency this week.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
-
- Discovery Partners International
- Inpharmatica Ltd.
- Sareum Holdings plc.
- ProSkelia